Read + Share
Dietz J, Sarrazin C. Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate
for hepatitis C virus retreatment in real-world settings". J Hepatol 2021 Apr 20. pii: S0168-8278(21)00252.
PMID: 33892009
|
 |
|
Dietz J, Sarrazin C. Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate
for hepatitis C virus retreatment in real-world settings". J Hepatol 2021 Apr 20. pii: S0168-8278(21)00252.
PMID: 33892009
|
|
|
|